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Summary
Background: Colonoscopic surveillance in patients with inflammatory bowel dis-
ease (IBD) leads to earlier detection of colorectal cancer (CRC) and reduces CRC-
associated mortality. However, it is limited by poor adherence in practice.
Aim: To identify missed opportunities to detect IBD-associated CRC at our hospital
Methods: We undertook root-cause analyses to identify patients with missed oppor-
tunities to diagnose IBD-associated CRC. We matched patients with IBD-associated 
CRC to patients with CRC in the general population to identify differences in staging 
at diagnosis and clinical outcomes.
Results: Compared with the general population, patients with IBD were at increased 
risk of developing CRC (odds ratio 2.7 [95% CI 1.6-3.9], P < 0.001). The mean inci-
dence of IBD-associated CRC between 1998 and 2019 was 165.4 (IQR 130.4-199.4) 
per 100 000 patients and has not changed over the last 20 years. Seventy-eight 
patients had IBD-associated CRC. Forty-two (54%) patients were eligible for CRC 
surveillance: 12% (5/42) and 10% (4/42) patients were diagnosed with CRC at an ap-
propriately timed or overdue surveillance colonoscopy, respectively. Interval cancers 
occurred in 14% (6/42) of patients; 64% (27/42) of patients had a missed opportunity 
for colonoscopic surveillance where root-cause analyses demonstrated that 10/27 
(37%) patients known to secondary care had not been offered surveillance. Four 
(15%) patients had a delayed diagnosis of CRC due to failure to account for previ-
ous colonoscopic findings. Seventeen (63%) patients were managed by primary care 
including seven patients discharged from secondary care without a surveillance plan. 
Matched case-control analysis did not show significant differences in cancer staging 
or 10-year survival outcomes.
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1  | INTRODUC TION
Colonoscopic surveillance leads to the earlier detection of colorectal 
cancer (CRC) in patients with inflammatory bowel disease (IBD) and 
may reduce CRC-associated mortality.1–4 International guidelines rec-
ommend that surveillance programs begin 8-10 years after diagnosis 
of IBD in all but those patients whose disease is limited to the ileum or 
rectum.5–7 Thereafter, the surveillance interval is determined by the 
adequacy and endoscopic and/or histological findings of the previous 
colonoscopy. However, the effectiveness of colonoscopic surveillance 
in routine practice has been questioned because of poor adherence to 
surveillance protocols outside of clinical trials.8,9
Root-cause analyses were developed originally to recognise fac-
tors that cause variation in performance in high-risk organisations 
including aviation and nuclear power.10,11 In healthcare, they have 
been applied to complex systems to understand why adverse out-
comes occur. To prevent CRC, at-risk patients should be enrolled into 
surveillance programs so that pre-malignant lesions can be detected 
and completely resected. Because CRC can be diagnosed shortly 
after a normal colonoscopy, the World Endoscopy Organisation has 
constructed a root-cause analysis framework to identify why, so-
called post-colonoscopy cancers, occur.12,13 Using this tool to report 
factors linked to post-colonoscopy cancers in a mixed cohort of sur-
veillance patients, the authors from an academic endoscopy centre 
in the UK, recommend extra vigilance in patients with IBD.13
We sought to define the proportion of patients diagnosed with 
an IBD-associated CRC who had had a missed opportunity for col-
orectal surveillance and whether this influenced stage at diagnosis 
of CRC or survival outcomes.
2  | METHODS
2.1 | Study design and clinical setting
Using the World Endoscopy Organisation framework, we undertook 
a root-cause analysis to identify missed opportunities to diagnose 
IBD-associated CRC. We then designed a case-control matching 
study to define CRC survival outcomes in patients with IBD com-
pared to the general population.
The Royal Devon & Exeter NHS Trust is an acute hospital that 
serves 48 general practices and about 400 000 people in North, 
East and West Devon. We estimate that the prevalence of ulcer-
ative colitis (UC) and Crohn's disease is 479 per 100 000 and 266 per 
100 000 respectively.14
2.2 | Case identification and data acquisition
Structured CRC outcome data have been collected prospectively 
since 1998 (Dendrite Clinical Systems LTD). We cross-referenced 
all patients diagnosed with CRC between March 1998 and March 
2019 with our IBD database (Infoflex, Chameleon Information 
Management Services) to identify patients with IBD-associated 
CRCs. Patients were excluded from the study if they were diagnosed 
with IBD after the diagnosis of CRC.
Two researchers (C.G and D.C) retrieved data from paper and 
electronic medical records and our endoscopy (Unisoft GI report-
ing tool, HD Clinical) and histology databases (Swift Integrated 
Healthcare Solutions DXC Technology Company). Variables re-
corded included patient demographics (age, sex, ethnicity, smoking 
status, comorbidities according to the Charlson Comorbidity Index), 
IBD history (disease duration and phenotype according to the 
Montreal classification previous and concomitant medical therapies, 
IBD-related surgeries and treating physician) and colonoscopic sur-
veillance history (family history of CRC, primary sclerosing cholangi-
tis, endoscopic/histological findings at the last test including quality 
of bowel preparation, completion, disease activity, dysplasia, stric-
tures and post-inflammatory polyps).15,16 Data regarding tumour lo-
cation, stage at diagnosis and survival outcomes were also obtained 
from a CRC disease database.
2.3 | Root-cause analysis
Each pseudonymised surveillance history was reviewed by four gas-
troenterologists and we applied the following root-cause analysis 
steps to define the proportion of patients who had a missed op-
portunity for surveillance. Discrepancies were resolved by further 
review of source documents.
Step 1: Did the patient meet contemporaneous criteria for CRC 
surveillance of their IBD at the time their CRC was diagnosed?
If no, the patient was removed from our root-cause analysis; if 
yes, we proceeded to step 2.
Step 2: Considering the patient's age, comorbidities and personal 
preferences was surveillance indicated/appropriate?
If no, the patient was removed from our root-cause analysis; if 
yes, we proceeded to step 3.
Step 3: Was the CRC diagnosed at a surveillance colonoscopy?
If no, proceed to step 5; if yes, proceed to step 4.
Step 4: Was the surveillance colonoscopy which diagnosed the 
CRC performed within the correct time interval (no later than 3 
Conclusion: The incidence of IBD-associated CRC has remained static. Two-thirds of 
patients eligible for colonoscopic surveillance had missed opportunities to diagnose 
CRC. Surveillance programmes without comprehensive and fully integrated recall 
systems across primary and secondary care are set to fail.
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months after the recommended interval according to contempora-
neous IBD surveillance guidelines)?
If yes, the case was categorised as ‘A’: CRC diagnosed at timely 
surveillance colonoscopy.
If no, the case was categorised as ‘B’: CRC diagnosed at overdue 
surveillance colonoscopy.
Step 5: Had the patient been receiving optimal surveillance, ac-
cording to contemporaneous guidelines, prior to the diagnosis of 
CRC?
If yes, the case was categorised as ‘C’: interval cancer.
If no, the case was categorised as ‘D’: missed opportunity to di-
agnose CRC.
2.4 | Case-control analysis to define survival 
outcomes of patients with IBD-associated CRC
We compared CRC stage at diagnosis in patients with and without 
IBD. Patients with recurrent CRC and those referred from outside 
our catchment area were excluded to mitigate selection and tertiary 
referral bias. We then matched each case of IBD-associated CRC to 
four control patients, with CRC but not IBD, for age, sex, tumour 
location and stage.17 We report all-cause mortality in cases and 
controls subsequently stratified by the outcome of our root-cause 
analysis (A–D).
2.5 | Statistical methods
This study was designed as a service evaluation so a priori power 
calculations were not undertaken. Pseudonymised data were 
managed using REDCap electronic data capture tools hosted 
at the Royal Devon and Exeter NHS Trust and statistical anal-
yses were undertaken in R 3.6.1 (R Foundation for Statistical 
Computing).18 All analyses were two tailed and P < 0.05 were 
considered significant. We included patients with missing clini-
cal data in analyses for which they had data and have specified 
the denominator for each variable. Descriptive statistics are 
reported as median and interquartile range for continuous vari-
ables and as number and proportions for categorical variables, 
unless otherwise stated.
The incidence of IBD-associated CRC was defined as the num-
ber of new cases of CRC occurring in patients with IBD. We report 
the mean incidence expressed per 100 000 persons per year be-
tween March 1998 and March 2019 and sought temporal changes 
in the incidence of CRC in patients with and without IBD using 
linear regression analyses. We report the number of patients who 
were adjudicated as having had a timely (A) or overdue (B) diagno-
sis, interval cancer (C) or missed opportunity for surveillance (D), 
as a proportion of the total number of patients eligible for surveil-
lance. We matched patients with IBD-related CRC to CRC patients 
without IBD using the optimal method in the MatchIt package in 
R for sex, age at diagnosis, stage and location of cancer.19 Survival 
rates were estimated using the Kaplan-Meier method and log-rank 
test.20
2.6 | Ethical considerations and patient involvement
Patients were not involved in the conception or design of this 
study. In accordance with UK Health Research Authority guide-




Among 4944 cases of colorectal adenocarcinoma diagnosed be-
tween March 1998 and March 2019: we identified 94 patients with a 
diagnosis of both IBD and CRC, representing 1.9% of all CRC treated 
at the Royal Devon and Exeter Hospital. Sixteen (16/94) of these 
cases were excluded as their IBD was diagnosed after their CRC, 
resulting in 78 cases of IBD-associated CRC. Patient disposition 
through the study is shown in (Figure 1).
The mean incidence of IBD-associated CRC in Devon from 1998 
to 2019 was 165.4 per 100 000 patients with IBD (IQR 130.4-199.4) 
when adjusted for year-on-year changes in IBD prevalence.14 The 
mean incidence of sporadic CRC in Devon is 61.8 per 100 000 pa-
tients (IQR 57.6-67.5). Patients with IBD were at higher risk of devel-
oping CRC (odds ratio 2.7 [95% CI 1.6-3.9], P < 0.001). The incidence 
of CRC in patients with and without IBD has not changed signifi-
cantly over the last 20 years (Figure 2).
3.2 | Baseline characteristics
Overall, 65% (51/78) patients with IBD-associated CRC were male 
with a median age of 69.7 years [61.0-78.0]. Most patients were 
white Europeans (97% [76/78]) and 35% (27/78) were current or 
ex-smokers. Seventy-two percent of patients (56/78) had UC, 22% 
(17/78) patients had Crohn's disease and 6% (5/78) inflammatory 
bowel disease unclassified (IBD-U). The median age at diagnosis 
of IBD was 46.4 years [IQR 31.9-62.1] with a median disease dura-
tion of 21.2 years [IQR 8.1-33.9]. Disease extent for UC and IBD-U, 
was limited to the rectum (E1) in 5% (4/78), left-sided (E2) in 26% 
(20/78) and extensive or pan-colitis (E3) in 40% (31/78) of patients. 
Crohn's disease was limited to the colon (L2) in 8% (6/78) and in-
volved the ileum and colon (L3) in 10% (8/78) patients. Any family 
history of CRC was too poorly recorded to allow meaningful analysis. 
Three patients were diagnosed with primary sclerosing cholangitis. 
At the time of CRC diagnosis, 45% (35/78) patients were not being 
treated with any medications for their IBD; 41% (32/78) patients 
were treated with an aminosalicylate and/or immunosuppressant 
and one patient was treated with adalimumab (Table 1).
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At CRC diagnosis, 14% (11/78), 40% (31/78), 26% (20/78) and 
20% (15/78) patients had Stage I, II, III and IV disease respectively. 
One patient did not have adequate staging data available. In total 
39% (30/78) patients had rectal cancer, followed by 36% (28/78) 
with right-sided colon cancer, 21% (16/78) with sigmoid cancer 
and 4% (3/78) with descending colon cancer. Of the rectal cancers, 
9% (7/78) of CRCs occurred in patients with retained rectums post 
subtotal colectomy for severe UC: 6% (5/78; 4 UC and 1 IBD-U) 
with an end ileostomy and rectal stump and 3% (2/78; 2 Crohn's 
disease) with an ileo-rectal anastomosis. In addition, there was 
one case where CRC occurred in the rectal stump of a patient with 
a defunctioning colostomy for perianal Crohn's disease.
3.3 | Root-cause analysis outcomes
At step 1, we removed 36% (28/78) patients because they did not 
meet contemporaneous criteria for CRC surveillance. Seven pa-
tients were diagnosed with IBD and CRC at the index colonoscopy. 
Ten patients had had IBD for less than 10 years (median age at CRC 
diagnosis 70.2 years [IQR 71.1-78.2], disease duration of 4.3 years 
[IQR 2.3-5.6]). Five patients had proctitis (E1: n = 3) or ileitis (L1: 
n = 2) only, whose cancers occurred in areas of the colon that had 
not previously been affected by IBD. Six patients had too much 
missing data to allow us to determine if they met surveillance cri-
teria or not.
At step 2, we removed 10% (8/78) patients: Six patients because 
of advanced age (median age 83.3 years [range 81.5-88.4]) and/or 
significant comorbidities (mean Charlson Comorbidity Index of 6.5 
[IQR 6-7]) and two who had opted out of surveillance.
In the 42 patients eligible and suitable for surveillance: 12% 
(5/42) and 10% (4/42) patients were diagnosed with CRC at an ap-
propriately timed (A) or overdue surveillance colonoscopy (B) re-
spectively. Interval cancers (C) were observed in 14% (6/42) patients, 
64% (27/42) patients had a missed opportunity (D) for colonoscopic 
surveillance (Figure 1).
Of the 42 patients eligible for surveillance, 6 (14%) patients had 
prior dysplasia. Four patients had intensified surveillance which led 
F I G U R E  1   Patient flow diagram. IBD, inflammatory bowel disease; CRC, colorectal cancer; RDE, Royal Devon and Exeter Hospital; E1, 
Montreal Classification Extent 1 (ulcerative proctitis); L1, Montreal Classification Location 1 (terminal ileal).
True cases of CRC with IBD (78)
Eligible for surveillance (42)
Patients with IBD and CRC (94)
• IBD diagnosed after CRC (16)
• Disease duration < 10 years (10) 
• IBD and CRC diagnosed concurrently (7)
• Missing data / unable to assess (6)
• Limited disease extent (E1 or L1) (5)
Did not meet surveillance 
criteria at time of cancer 
(28) 
Excluded (16)
Cases of Colorectal Cancer in IBD patients at RDE March 1998 to March 2019
Patient not entered/ 
withdrawn from 
surveillance (8)
• Age/ comorbidity (6)
• Patient declined or non-adherent (2)
Optimal surveillance (11) Suboptimal/no surveillance (31)
CRC diagnosed 
during surveillance
CRC not diagnosed 
during surveillance
Timely surveillance diagnosis
(A) = 5 (12%)
Interval cancer
(C) = 6 (14%)
Overdue surveillance
(B) = 4 (10%)
Missed opportunity
(D) = 27 (64%)
Step 1
Did the patient meet 
contemporaneous criteria for 
CRC surveillance of their IBD?
Step 2
Was surveillance indicated/ 
appropriate given age/ 
comorbidities/ preference?
Step 3
Was CRC diagnosed at a
surveillance colonoscopy?
Step 4
Was surveillance colonoscopy 
performed within  the correct 
time interval?
Step 5
Had the patient being receiving   
optimal surveillance?
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to the timely detection of CRC. One patient was a missed opportu-
nity due to failure to intensify surveillance for low grade dysplasia 
and the other was diagnosed at an overdue surveillance colonoscopy 
where a planned proctocolectomy for severe pan-colitis with dyspla-
sia was delayed by the patient.
Of those patients with a missed opportunity for colonoscopic 
surveillance (D), 52% (14/27) were male, with a median age at CRC 
diagnosis of 64.9 years (IQR 60.4-74.3) and median disease dura-
tion of 24.8 years (IQR 15.4-32.4). Most patients (82% [22/27]) 
had UC: 45% (10/22) with extensive (E3) disease. Thirty seven 
percent (10/27) were current or ex-smokers. Only 11% (3/27) had 
previous surgeries for IBD. Eight cancers were located in the rec-
tum, 10 in the sigmoid or descending colon and nine in the as-
cending colon. With regard to CRC stage at diagnosis, 15% (4/27), 
44% (12/27), 22% (6/27) and 19% (5/27) had Stage 1, 2, 3 and 
4 respectively. When the suboptimal surveillance group (overdue 
surveillance [B] and missed opportunity [D]) was compared with 
patients who had CRC detected by optimal surveillance (timely 
surveillance [A] and interval cancer groups [C]), the factors sig-
nificantly associated with suboptimal surveillance were ulcerative 
colitis phenotype, older age at IBD diagnosis and the absence of 
resectional surgery (Table 2). Overall, 67% (17/27) of patients with 
a missed opportunity for surveillance were being managed in pri-
mary care leading up to their CRC diagnosis (Table 2, Table S1): 
Seven patients had been discharged back to primary care by either 
a gastroenterologist or surgeon without a plan for surveillance and 
10 patients were unknown to secondary care. Of the patients with 
a missed opportunity, 37% (10/27) had not been offered surveil-
lance despite on-going secondary care follow-up. In 15% (4/27) 
of patients, inadequacy of previous colonoscopies and/or failure 
to take into account previous histological findings contributed to 
delay in diagnosis of CRC.
3.4 | Case-control analysis to define survival 
outcomes of patients with IBD-associated CRC
We excluded 1/78 cases of IBD-associated colon cancer because 
missing staging data meant we were unable to perform matching. 
Between 1998 and 2019, 4850 patients without IBD were diagnosed 
with CRC in our catchment area. These patients were older at di-
agnosis (72.6 years [IQR 66.0-81.0] vs 67.3 years [IQR 60.9-77.9]) 
than patients with IBD-associated CRC, however, there were no sig-
nificant differences in age at cancer diagnosis, sex, location, stage of 
CRC at diagnosis or survival (Table 3).
The Kaplan-Meier estimated probability of survival in IBD-
associated CRC was 53.7% [90% CI 43.1-66.9] at 5 years and 38.5% 
[27.1-50.0] at 10 years (Figure 3). After matching for sex, age at 
diagnosis, stage and location of cancer, there were no differences 
in survival between patients with IBD-related or sporadic CRC 
(Figure 3) even in patients with a missed opportunity for surveillance 
(Figure S1).
F I G U R E  2   Incidence of IBD-associated and sporadic colorectal cancer (corrected for population changes year-on-year). CRC, colorectal 






































Case rate of IBD-associated CRC (orange) corrected for IBD prevalence 
 and sporadic CRC (black) corrected for Devon population over time
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Not eligible for 
surveillance P
n (%) or median [IQR] 78 42 36
Age at IBD diagnosis, y 46.4 [31.9-62.1] 36.9 [22.7-49.0] 58.0 [36.8-71.4] <0.001
Age at CRC diagnosis, y 69.7 [61.0-78.0] 64.8 [58.7-73.3] 75.5 [66.9-81.5] 0.003
Sex
Male 51 (65) 26 (62) 25 (69) 0.646
Female 27 (35) 16 (38) 11 (31)
Ethnicity
White 76 (97) 40 (95) 36 (100) 0.543
Asian 2 (3) 2 (5) 0 (0)
Smoking history
Never smoker 40 (51) 21 (50) 19 (53) 0.666
Current smoker 3 (4) 1 (2) 2 (6)
Ex-smoker 24 (31) 15 (36) 9 (25)
Not known 11 (14) 5 (12) 6 (17)
IBD phenotype
Ulcerative colitis 56 (72) 30 (71) 26 (72) 0.959
Crohn's disease 17 (22) 9 (21) 8 (22)
IBD-U 5 (6) 3 (7) 2 (6)
Montreal (A)
A1 4 (5) 2 (5) 2 (6) 0.412
A2 30 (39) 19 (45) 11 (31)
A3 44 (56) 21 (50) 23 (64)
Montreal (E)—UC only
E1 4 (5) 0 (0) 4 (11) 0.007
E2 20 (26) 16 (38) 4 (11)
E3 31 (40) 17 (41) 14 (39)
Montreal (L)—CD only
L1 2 (3) 0 (0) 2 (6) 0.098
L2 6 (8) 3 (7) 3 (8)
L3 8 (10) 6 (14) 2 (6)
Duration of IBD to CRC diagnosis, y 46.4 [31.9-62.1] 24.8 [16.4-33.9] 5.9 [1.5-32.8] 0.002
Interval from last endoscopy to CRC diagnosis, y 2.3 [0-6.4] 4.3 [1.1-7.6] 2.7 [0.0-7.8] 0.256
Family history of CRC
Yes 6 (8) 4 (10) 2 (6) 0.745
No 30 (39) 15 (36) 15 (42)
Unknown 42 (54) 23 (55) 19 (53)
Primary sclerosing cholangitis 3 (4) 3 (7) 0 (0) 0.096
At least one major comorbidity 36 (46) 19 (45) 17 (47) 1
Medication history
None 35 (45) 13 (31) 22 (61) n/a
Steroids 9 (12) 7 (17) 2 (6)
5ASA only 27 (35) 12 (29) 15 (42)
Thiopurine/methotrexate only 4 (5) 4 (10) 3 (8)
Biologics 1 (1) 1 (2) 0 (0)
(Continues)




Not eligible for 
surveillance P
Surgical history
Subtotal colectomy and end ileostomy 5 (6) 4 (10) 1 (3) 0.454
Subtotal colectomy and anastomosis 2 (3) 2 (5) 0 (0)
Defunctioning colostomy 1 (1) 1 (2) 0 (0)
Abbreviations: 5ASA, 5-aminosalicylates; CD, Crohn's disease; CRC, colorectal cancer; IBD, inflammatory bowel disease; IBD-U, inflammatory bowel 
disease unclassified; IQR, interquartile range; Montreal (A), Montreal Classification Age; Montreal (E), Montreal Classification Extent; Montreal (L), 
Montreal Classification Location; UC, ulcerative colitis.
TA B L E  1   (Continued)
TA B L E  2   Optimal surveillance vs suboptimal surveillance
Optimal surveillance  
(A + C)
Suboptimal surveillance 
(B + D) P
n 11 31
Sex (%)
Male 9 (82) 17 (55) 0.222
Female 2 (18) 14 (45)
Smoking status (%)
Never smoker 6 (55) 15 (48) 0.751
Current smoker 0 (0) 1 (3)
Ex-smoker 3 (27) 12 (39)
Not known 2 (18) 3 (10)
IBD phenotype (%)
Ulcerative colitis 4 (36) 26 (84) 0.01
Crohn's disease 5 (46) 4 (13)
IBD-U 2 (18) 1 (3)
Age at IBD diagnosis, years (median [IQR]) 21.1 [19.4-34.6] 43.8 [30.4-49.3] 0.044
Primary sclerosing cholangitis (%) 1 (9) 3 (10) 1
Previous immunomodulator (%) 4 (36) 6 (19) 0.468
Previous biologic (%) 1 (9) 2 (7) 1
Previous bowel resection (%) 6 (55) 3 (10) 0.007
Age at CRC diagnosis, years (median [IQR]) 62.3 [45.7-71.5] 66.4 [60.4-73.6] 0.271
CRC stage (%)
1 0 (0) 6 (19) n/a
2 6 (55) 13 (42)
3 4 (36) 7 (23)
4 1 (9) 5 (16)
CRC location (%)
Rectum 7 (64) 10 (32) 0.205
Rectosigmoid 0 (0) 6 (19)
Right colon 3 (27) 11 (36)
Sigmoid 0 (0) 3 (10)
Descending colon 1 (9) 1 (3)
Managed by (%)
Secondary care 10 (64) 14 (36) 0.065
Primary care (GP) 1 (9) 17 (52)
Abbreviations: CRC, colorectal cancer; GP, general practitioner; IBD, inflammatory bowel disease; IBD-U, inflammatory bowel disease unclassified; 
IQR, interquartile range.
298  |     GORDON et al.
4  | DISCUSSION
4.1 | Key results and interpretation
Our patients with IBD are at increased risk of CRC, and irrespective 
of our current surveillance practice this has not changed over time 
(Figure 2). Overall, two-thirds of patients had a missed opportunity 
for surveillance. However, this delay in diagnosis did not influence 
stage of CRC at presentation or survival outcomes.
Based on our findings and those from another recent study that 
used primary care records to identify cases and thereby control 
for tertiary centre bias, the incidence of CRC in IBD appears to be 
static.14,22,23 It is contrary, however, to data from specialist endos-
copy centres and from prospective population studies from Nordic 
countries that have reported falling CRC incidence rates.24–27 It is 
unclear why CRC rates have fallen in Denmark, Norway and Sweden 
but not the UK over a similar timeframe, since it is likely that all 
four countries have adopted similar treatment-targets: including 
the maintenance of remission with medical therapies, appropri-
ately timed surgeries and the use of colorectal surveillance pro-
grammes.23,28–30 Static CRC rates amongst IBD patients in the UK 
may reflect poor integration between primary and secondary care 
services, impacting surveillance recall. In our cohort, for example, 
two-thirds of patients with a missed opportunity for CRC surveil-
lance were being cared for exclusively by their general practitioner, 
nearly half of whom had been discharged by secondary care without 
a surveillance plan. Surveillance programmes without comprehen-
sive recall systems are set to fail.
Our observation that one-third of IBD-associated CRCs were 
diagnosed in patients who were perceived to be at low-risk be-
cause of limited disease duration or extent, where surveillance 
had not started, is concerning. Whilst CRC is rarely encountered 
in the first few years of disease, early-onset IBD-related CRCs 
have been reported,30 in particular in patients with concomitant 
primary sclerosing cholangitis.31 It may be that these patients had 
active IBD for many years prior to diagnosis. Even if we applied the 
most recent British Society of Gastroenterology guidelines 6 that 
currently recommend commencing surveillance from eight years 
after diagnosis or onset of symptoms (if there was a significant 
delay before diagnosis) to all cases, only two additional patients 
would have been eligible for surveillance. Five sporadic CRCs were 
observed in segments of the colon previously unaffected by IBD. 
Whether more vigilance is required in patients who have isolated 
ileitis or proctitis who are reportedly not at increased risk of IBD 
is less clear. Adequate histological mapping to avoid underestima-
tion of disease extent is clearly important, in particular, in patients 
phenotyped as having proctitis because they will not be enrolled 
in surveillance programs.32–35 Five patients developed CRC in their 
rectal stump after undergoing subtotal colectomies, hence it is 
important that these patients are also retained in a surveillance 
database.
Less clarity exists as to when to stop CRC surveillance. In our co-
hort, of the six patients who were deemed ineligible for surveillance 
due to their age and/or comorbidities, three underwent successful 
curative surgery. Arbitrary age cut-offs risk underuse of screening in 
healthy older patients. In IBD, individualised discussions taking into 




(n = 307) P
Unmatched controls 
(n = 4529) P
Sex (male, %) 50 (65) 198 (64) 1.00 2282 (50) 0.047
Age at CRC diagnosis, years  
[median, IQR]
69.5 [61.0-78.0] 67.0 [59.1-75.0] 0.302 74.0 [66.0-81.0] <0.001
Stage of CRC (%)
1 11 (14) 21 (7) 0.093 489 (11) 0.536
2 31 (40) 133 (43) 1835 (41)
3 20 (26) 68 (22) 1288 (28)
4 15 (20) 86 (28) 915 (21)
Location of CRC (%)
Right colon 28 (36) 100 (33) 0.512 1605 (35) 0.121
Descending colon 3 (4) 20 (7) 241 (5)
Other 0 (0) 0 (0) 175 (4)
Rectum 30 (39) 105 (34) 1292 (29)
Sigmoid 16 (21) 83 (27) 1227 (27)
Survival [%, 95% CI]
5-year 53.7 [43.1-66.9] 52.2 [46.9-58.1] 0.76 49.8 [48.4-51.3] 0.33
10-year 38.5 [27.1-50.0] 42.5 [37.3-48.4] 36.4 [34.8-38.0]
Abbreviations: CI, confidence interval; CRC, colorectal cancer; IBD, inflammatory bowel disease; IQR, interquartile range.
aOne IBD patient was excluded from matching based on missing staging data. 
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life expectancy as opposed to age, risk factors for IBD-associated 
CRC and consecutive negative findings at previous colonoscopies, 
seem appropriate.36,37
4.2 | Limitations and generalisability
We acknowledge the following important limitations: first, we 
collected data from over 20 years and applied CRC surveillance 
guidelines in place at the time of cancer diagnosis: arguably, using 
a common set of guidelines would have decreased heterogene-
ity in data handling. Second, we relied on retrospective case note 
and database review and our data are limited by missingness and 
subject to interpretation bias. Third, our sample size, in particu-
lar, after excluding patients who were not eligible for surveillance 
was small and precluded subgroup analyses. Moreover, we were 
underpowered to detect the small differences in survival between 
patients with IBD-related and sporadic CRCs that have previously 
been observed. In this study, we excluded patients living outside 
our catchment area, so our results are likely to be generalisable to 
non-tertiary centres in the UK. Whether other UK regions have 
similar proportions of patients managed exclusively in primary care 
has not been studied.
Accepting that the quality of the evidence is limited, with close 
concordance to surveillance guidelines, colonoscopic surveillance 
in IBD reduces the development of CRC and associated mortality 
through earlier detection and removal of pre-malignant lesion.22,27,38 
Whilst artificial intelligence and non-invasive biomarkers of dysplasia 
are likely to increase the sensitivity of surveillance procedures, these 
newer techniques have not yet translated to routine clinical care.39 
In the meantime, we have designed a recall system embedded in our 
electronic record that prompts physicians when surveillance is due, 
and have completed a case finding survey in primary care.
5  | CONCLUSION
The incidence of IBD-associated colorectal has remained static. 
Two-thirds of patients eligible for colonoscopic surveillance had a 
missed opportunity to diagnose CRC. Surveillance programmes 
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without comprehensive and fully integrated recall systems across 
primary and secondary care are set to fail.
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